This polymorphism reinforces ADCC in vivo, such that, for example, patients with lymphoma that are homozygous for CD16-158V show substantially higher response rates after treatment with rituximab than those with CD16-158F polymorphism [111,112,113]. The gene discussed is FCGR3A; the disease is lymphoma.